1. Home
  2. GANX vs FLNT Comparison

GANX vs FLNT Comparison

Compare GANX & FLNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • FLNT
  • Stock Information
  • Founded
  • GANX 2017
  • FLNT 2010
  • Country
  • GANX United States
  • FLNT United States
  • Employees
  • GANX N/A
  • FLNT N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • FLNT Advertising
  • Sector
  • GANX Health Care
  • FLNT Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • FLNT Nasdaq
  • Market Cap
  • GANX 41.9M
  • FLNT 49.6M
  • IPO Year
  • GANX 2021
  • FLNT N/A
  • Fundamental
  • Price
  • GANX $1.85
  • FLNT $2.82
  • Analyst Decision
  • GANX Strong Buy
  • FLNT Hold
  • Analyst Count
  • GANX 4
  • FLNT 1
  • Target Price
  • GANX $7.75
  • FLNT $4.00
  • AVG Volume (30 Days)
  • GANX 281.8K
  • FLNT 13.0K
  • Earning Date
  • GANX 11-14-2024
  • FLNT 11-14-2024
  • Dividend Yield
  • GANX N/A
  • FLNT N/A
  • EPS Growth
  • GANX N/A
  • FLNT N/A
  • EPS
  • GANX N/A
  • FLNT N/A
  • Revenue
  • GANX N/A
  • FLNT $261,976,999.00
  • Revenue This Year
  • GANX N/A
  • FLNT N/A
  • Revenue Next Year
  • GANX $300.03
  • FLNT $13.16
  • P/E Ratio
  • GANX N/A
  • FLNT N/A
  • Revenue Growth
  • GANX N/A
  • FLNT N/A
  • 52 Week Low
  • GANX $0.89
  • FLNT $2.31
  • 52 Week High
  • GANX $5.33
  • FLNT $4.80
  • Technical
  • Relative Strength Index (RSI)
  • GANX 39.86
  • FLNT 42.92
  • Support Level
  • GANX $1.64
  • FLNT $2.91
  • Resistance Level
  • GANX $2.34
  • FLNT $3.20
  • Average True Range (ATR)
  • GANX 0.27
  • FLNT 0.15
  • MACD
  • GANX -0.09
  • FLNT -0.01
  • Stochastic Oscillator
  • GANX 19.90
  • FLNT 2.51

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

About FLNT Fluent Inc.

Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers they are seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.

Share on Social Networks: